PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study [version 2; peer review: 2 approved]

Julian Rogasch1*, Marcus Beck2*, Carmen Stromberger2, Frank Hofheinz3, Pirus Ghadjar2, Peter Wust2, Volker Budach2, Holger Amthauer1, Ingeborg Tinhofer2,4, Christian Furth1, Thula C. Walter-Rittel5*, Sebastian Zschaecck2,6*

1Department of Nuclear Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany
2Department of Radiation Oncology, Charité-Universitätsmedizin Berlin, Berlin, Germany
3Research Center Dresden-Rossendorf, Dresden, Germany
4German Cancer Research Center, Heidelberg, Germany
5Department of Diagnostic and Interventional Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany
6Berlin Institute of Health (BIH), Berlin, Germany

* Equal contributors

v2 First published: 19 Nov 2020, 9:1350
https://doi.org/10.12688/f1000research.27303.1
Latest published: 16 Mar 2021, 9:1350
https://doi.org/10.12688/f1000research.27303.2

Abstract

Background: Tumor hypoxia measured by dedicated tracers like [18F]fluoromisonidazole (FMISO) is a well-established prognostic factor in head and neck squamous cell carcinomas (HNSCC) treated with definitive chemoradiation (CRT). However, prevalence and characteristics of positron emission tomography (PET) measured hypoxia in patients with relapse after previous irradiation is missing. Here we report imaging findings of a prospective pilot study in HNSCC patients treated with re-irradiation.

Methods: In 8 patients with recurrent HNSCC, diagnosed at a median of 18 months after initial radiotherapy/CRT, [18F]fluorodeoxyglucose (FDG)-PET/CT (n=8) and FMISO-PET/MRI (n=7) or FMISO-PET/CT (n=1) were performed. Static FMISO-PET was performed after 180 min. MRI sequences in PET/MRI included diffusion-weighted imaging with apparent diffusion coefficient (ADC) values and contrast enhanced T1w imaging (StarVIBE). Lesions (primary tumor recurrence, 4; cervical lymph node, 1; both, 3) were delineated on FDG-PET and FMISO-PET data using a background-adapted threshold-based method. SUV\textsubscript{max} and SUV\textsubscript{mean} in FDG- and FMISO-PET were derived, as well as maximum tumor-to-muscle ratio (TMR\textsubscript{max}) and hypoxic volume with...
1.6-fold muscle SUV\textsubscript{mean} (HV\textsubscript{1.6}) in FMISO-PET. Intensity of lesional contrast enhancement was rated relative to contralateral normal tissue. Average ADC values were derived from a 2D region of interest in the tumor.

**Results:** In FMISO-PET, median TMR\textsubscript{max} was 1.7 (range: 1.1-1.8). Median HV\textsubscript{1.6} was 0.05 ml (range: 0-7.3 ml). Only in 2/8 patients, HV\textsubscript{1.6} was \( \geq 1.0 \) ml. In FDG-PET, median SUV\textsubscript{max} was 9.3 (range: 5.0-20.1). On contrast enhanced imaging four lesions showed decreased and four lesions increased contrast enhancement compared to non-pathologic reference tissue. Median average ADC was 1,060 \( \times \) 10\textsuperscript{6} mm\textsuperscript{2}/s (range: 840-1,400 \( \times \) 10\textsuperscript{6} mm\textsuperscript{2}/s).

**Conclusions:** This pilot study implies that hypoxia detectable by FMISO-PET may not be as prevalent as expected among loco-regional recurrent, HPV negative HNSCC. ADC values were only mildly reduced, and contrast enhancement was variable. The results require confirmation in larger sample sizes.

**Keywords**
radiotherapy, head and neck squamous cell carcinoma, hypoxia, FMISO, positron emission tomography, FDG, PET

This article is included in the Oncology gateway.
Introduction

Locally advanced head and neck squamous cell carcinomas (HNSCC) that are not associated with human papillomavirus (HPV) infections have an unfavorable prognosis. Standard treatment consists of definitive chemoradiation (CRT) with radiation doses of around 70 Gray (Gy). Acute toxicity is considerable and dose limiting in this approach. Nonetheless, about 50% of patients present with local or regional recurrence after definitive CRT. Re-irradiation is frequently chosen in cases with recurrence at the primary tumor site or regional lymph nodes. Due to radiation-induced long-term sequelae of the surrounding organs at risk, the re-irradiation dose is usually lower than in the primary setting. Consequently, tumors that are apparently radioresistant are treated with lower radiation doses than those applied in the primary situation. Not surprisingly, this approach is associated with a very unfavorable outcome. Especially in HPV negative tumors that are unresectable, re-irradiation is merely a palliative approach.

One important factor of radioresistance is tumor hypoxia. Hypoxia is associated with a more aggressive tumor phenotype as shown by various studies of different tumor entities. Additionally, when treating patients with photon radiotherapy, hypoxia leads to a decreased cytotoxic effect of irradiation due to the lower availability of oxygen radicals. This effect can be specified by calculating the oxygen enhancement ratio (OER). Usually the OER is between two and four, which further underlines the important and strong effect of hypoxia in radiotherapy. One sophisticated method to measure hypoxia non-invasively is positron emission tomography (PET) with hypoxia specific radiotracers. The most commonly used hypoxia radiotracer is \([^{18}F]fluoromisonidazole\) (FMISO). PET measured hypoxia provides a substantial and independent prognostic value in patients undergoing primary CRT for HNSCC. Re-oxygenation, measured by repeated hypoxia PET during treatment, seems to be of even greater prognostic relevance in HNSCC with hardly any local tumor control in case of residual tumor hypoxia during the second week of CRT. Given these data, we postulated that PET measured tumor hypoxia should also play an important role in local recurrent HNSCC after prior radiotherapy. To improve patient outcome by increasing re-oxygenation during CRT, a prospective pilot study was initiated to evaluate the effect of fever-range whole-body hyperthermia (FRWBH) on the tumor microenvironment in patients with re-irradiation for HNSCC. FRWBH has been shown to increase tumor perfusion in preclinical models and the rationale of the GKH-TMM trial was to increase tumor perfusion and subsequently reduce tumor hypoxia by adding weekly FRWBH to re-irradiation. The primary endpoint of the trial was feasibility of FRWBH, which will be published separately when mature outcome data of patients are available. Secondary endpoints included changes of hypoxia and perfusion between pre-treatment and second week of fractionated CRT. Due to the lack of PET detectable hypoxia prior to treatment, we were not able to calculate these planned secondary outcome parameters. Here we report the imaging findings of the pretherapeutic PET and MRI scans within this trial.

Methods

The GKH-TMM, ARO-2018-3, study was registered at clinical trials (ClinicalTrials.gov identifier NCT03547388) and has been approved by the local Ethics committee (Charité Ethics committee, campus Virchow, EA2-047-18). All patients provided written informed consent to participate in the study and to publish results in a pseudonymized way.

The article complies with the reporting guidelines for observational studies (STROBE).

Study design

The GKH-TMM study was a prospective Phase-I study to evaluate the effect of FRWBH on the tumor microenvironment. Inclusion criteria for this study were as follows: unresectable local, regional or loco-regional recurrent non HPV-associated HNSCC with prior high-dose radiotherapy of the head and neck region (either as definitive or as adjuvant CRT or radiotherapy), time interval between previous radiotherapy and recurrence between 6 months and 5 years, complete whole-body staging without evidence of distant metastases by \([^{18}F]fluorodesoxyglucose\) (FDG)-PET/CT, Eastern Cooperative Oncology Group (ECOG) performance status between zero and two, and age between 18 and 75 years. Prior definitive CRT was applied according to clinical guidelines with 32 fractions and simultaneous integrated boost (SIB) with 1.7 Gy single dose to elective nodal volume, 1.9 Gy to macroscopic lesions with enlarged safety margins and 2.2 Gy reduced safety margins. adjuvant CRT for high-risk patients was delivered in 30 fractions with SIB (1.8 Gy elective nodal treatment and 2.13 Gy to high-risk regions).

The study was designed as a pilot study with ten patients, who were recruited between April 2018 and March 2020. Eligible patients were asked to take part in the trial as a complementary method to routine treatment. The evaluation of tumor microenvironment was performed by pre-therapeutic FMISO-PET in combination with magnetic resonance imaging (MRI) with diffusion weighted imaging (DWI and ADC maps) and contrast enhanced high resolution imaging (post contrast T1w StarVIBE). FMISO-PET was scheduled prior to therapy...
and repeated at the end of the second week of CRT in case of evidence for pre-therapeutic hypoxia.

**Patients and treatment**

Eight out of ten patients had pre-therapeutic FMISO-PET images. In two patients, FMISO-PET could not be performed due to logistical reasons. Out of the eight patients, seven patients underwent integrated PET/MRI, while one patient had to be examined by PET/CT due to severe claustrophobia.

All patients underwent hyperfractionated re-irradiation with two fractions of radiotherapy (1.2 Gy) per day and a minimum of eight hours between each fraction. Total treatment dose was 66 Gy, prescribed to the macroscopic tumor lesions plus 5 mm safety margin. Concomitant chemotherapy was not specified in the protocol but should preferentially include cisplatin due to its increased efficacy at mildly increased temperatures.

**FDG-PET/CT**

Pretherapeutic FDG-PET/CT was performed with a dedicated PET/CT scanner (Philips Gemini TF 16, Philips, Amsterdam, The Netherlands). FDG-PET was performed to exclude distant metastases and to guide radiation treatment volume, additionally it was planned to analyse geographic overlap between FDG and FMISO volumes. Patients were required to fast for at least 6 h prior to tracer injection, and a blood glucose level ≤ 130 mg/dl was validated. After intravenous injection of a median of 259 MBq [18F]FDG (interquartile range [IQR], 252 to 296 MBq/kg; median, 4.4 MBq/kg; IQR, 3.9 to 4.9 MBq/kg), static PET acquisition was performed after 80 min (IQR, 68 to 84 min) for 2 or 3 min per bed position from base of skull to proximal femora in supine position (matrix, 144 × 144). PET data were reconstructed iteratively using ordered subset expectation maximization (OSEM; BLOB-OS-TF) with 3 iterations and 33 subsets and time of flight (voxel size, 4.0 × 4.0 × 4.0 mm³) without resolution recovery (point spread function; PSF). Random correction, scatter correction and dead time correction were also included. Attenuation correction was performed based on a non-enhanced low-dose CT (slice thickness, 5 mm).

**FMISO-PET/CT**

Pretherapeutic FMISO-PET/CT was performed with a dedicated PET/MRI scanner (Biograph mMR, Siemens Healthcare, Erlangen, Germany). After intravenous administration of 208 MBq (IQR, 185 to 212 MBq) [13N]FMISO (median, 3.5 MBq/kg; IQR, 3.0 to 3.7 MBq/kg), static PET images of the relapse location in the head and neck region were acquired after 180 min (IQR, 172 to 221 min) in one bed position with an acquisition time of 15 min (matrix, 172 × 172). PET data were reconstructed iteratively using OSEM with 3 iterations, 21 subsets and a 3 mm Gaussian in-plane filter (voxel size, 4.17 × 4.17 × 2.03 mm³). Resolution recovery (point spread function) was not applied, and time of flight reconstruction was not available. Random correction, scatter correction and dead time correction were included. MR-based attenuation correction used the 3D CAIPIRINHA HiRes sequence (acceleration factor 5; voxel size, 1.3 × 1.3 × 3.0 mm³). Approximately five minutes after intravenous injection of 0.2 ml/kg of gadoteric acid (Dotarem, Guerbet, Roissy CdG Cedex, France; 0.5 mmol/ml; 4 ml/s, followed by a 25 ml bolus of saline solution), contrast-enhanced imaging was performed by T1w 3D in-plane radial sampling by a fat-suppressed spoiled-Gradient Echo core sequence (StarVIBE; TR, 4.91 ms; TE, 2.14 ms; flip angle (FA), 12°; field of view [FOV], 220 × 220 mm²; voxel size, 0.7 × 0.7 × 1.3 mm³). Diffusion-weighted imaging and apparent diffusion coefficient (ADC) maps of the tumor volume were acquired with a fat-saturated multi-shot readout-segmented echo-planar sequence (TR, 3840 ms; TE1, 61 ms; TE2, 100 ms; b1, 50 s/mm²; b2, 800 s/mm²; EPI factor 82; FA, 180°; FOV, 220 × 220 mm²; voxel size, 1.1 × 1.1 × 4.0 mm³); a pre- and post-contrast T1w Turbo Spin Echo (TSE) sequence (TR 692 ms; TE, 9 ms; FA, 142°; FOV, 180 × 180 mm²; voxel size, 0.6 × 0.6 × 3.0 mm³) and a T2w turbo -inversion recovery magnitude (TIRM) sequence (TR, 4510 ms; TE, 40 ms; FA, 140°; FOV, 200 × 200 mm²; voxel size, 0.6 × 0.6 × 3.0 mm³) were acquired. Parallel imaging was enabled by Generalized Autocalibrating Partially Parallel Acquisition (GRAPPA).

**Image evaluation**

Image analysis was performed as previously published and as shortly described in the following passage using ROVER software (version 3.0.50h; ABX, Radeberg, Germany; available freely for research purposes on request) without any preprocessing of the final image data. After co-registration of diagnostic FDG-PET/CT images and FMISO-PET/MRI or PET/CT images by the mutual information algorithm, correct alignment of the primary tumor volume was verified, and co-registration was corrected, if deemed necessary. The tumor (primary tumor recurrence or lymph node) was semi-automatically delineated in the PET images using a background-adapted threshold-based algorithm. Central necrotic tumor areas or areas that were suspicious of tumor in MRI or CT were subsequently included manually to the primary tumor/lymph node volume. A reference region of interest (ROI) was delineated in the deep neck muscles contralateral to the primary tumor with a spheroid of 16 mm diameter. The ROIs of the tumor and of the muscle were transferred to the hypoxia PET for calculation of the maximum standardized uptake value (SUVmax; normalized to the body weight) of the tumor, of the tumor-to-muscle ratio (TMR) and for thresholding of hypoxic volumes, e.g. the commonly used hypoxic volume with uptake above 1.6 times of the average muscle uptake (HV1.6).
The intensity of lesional contrast enhancement was rated by an experienced radiologist (9 years of experience) relative to the corresponding contralateral normal tissue using either the contrast-enhanced T1w images (StarVIBE sequence; n=7 patients) or the contrast-enhanced CT data (n=1 patient). Intensity was rated on a three point Likert-type item as “less intense”, “comparable intensity” or “more intense” compared to the contralateral reference tissue. Mean ADC values of the tumor lesions were measured by the same radiologist using representative 2D region of interest placed in the tumor volume.

Statistical analysis
Statistical analysis was performed using SPSS (version 26, IBM, Armonk, NY, USA). On the basis of the small sample size, non-normal data distribution was assumed, and descriptive data were expressed as median, IQR and range, unless otherwise specified.

Results
Eight patients with available pretherapeutic FMISO-PET imaging are reported here (PET/MRI, n=7; PET/CT, n=1). Characteristics of patients and treatment are summarized in Table 1.

Hypoxia in FMISO-PET
Assessment of tumor hypoxia in static FMISO-PET images three hours post injection revealed absence of detectable hypoxia in almost all patients. The median FMISO TMR$_{\text{max}}$ was 1.7 (IQR, 1.3 to 1.8; range, 1.1 to 1.8). Only two patients showed hypoxic volumes that were delineable using the 1.6-fold average background muscle activity threshold (HV$_{1.6}$). The median HV$_{1.6}$ of all 8 patients was 0.05 ml (IQR, 0 to 0.33 ml; range, 0 to 7.3 ml). Supplementary figure 1 and 2 show both patients with detectable HV$_{1.6}$ volumes and corresponding FDG PET CTs. As can bee seen, patient #4 shows scattered FMISO accumulation within and around the macroscopic lesion and only patient #6 shows a relatively well defined hypoxic volume within the macroscopic lesion. No lesion showed a TMR$_{\text{max}}$ >2.0. Notably, especially the largest recurrent lesions did not show any detectable hypoxia (HV$_{1.6}$ = 0 ml).

Uptake in FDG-PET
All lesions showed unequivocal and extensive FDG uptake (median MTV, 11.2 ml; IQR, 6.0 to 16.8 ml; range, 1.0 to 51.7 ml). The median SUV$_{\text{max}}$ was 9.3 (IQR, 8.4 to 13.6; range, 5.0 to 20.1), and the median SUV$_{\text{mean}}$ was 6.3 (IQR, 5.8 to 8.6; range, 3.0 to 12.6).

Details of FDG-PET and FMISO-PET parameters for all patients are shown in Table 2. Figure 1 shows exemplary FDG-PET/CT scans and FMISO-PET/MRI scans.

Contrast enhancement and ADC values
Tumor contrast enhancement was less intense compared to the contralateral reference in four of eight patients (lymph node only, n=1; primary tumor recurrence ± lymph node, n=3; Table 2). In the remaining four patients, enhancement was more intense, at least in parts of the lesion, compared to the reference tissue (primary tumor ± lymph node, n=4).

The median average ADC value was $1,060 \times 10^6 \text{mm}^2/\text{s}$ (IQR, $1,025 \text{ to } 1,211 \times 10^6 \text{mm}^2/\text{s}$; range, 840 to $1,400 \times 10^6 \text{mm}^2/\text{s}$).

Discussion
Here we report pretrial data from the first trial that evaluated tumor hypoxia by specific hypoxia PET in previously irradiated, recurrent HNSCC. Data on hypoxia measured by PET tracers in the recurrent disease situation after radiotherapy is

---

**Table 1. Patient and treatment characteristics.** abbreviations: OC = oral cavity, OP = oropharynx, HP = hypopharynx, def CRT = definitive chemoradiation, adj CRT = adjuvant chemoradiation, T = local recurrence, N = regional recurrence.

<table>
<thead>
<tr>
<th>Patient Number</th>
<th>Age</th>
<th>Gender</th>
<th>Primary tumor location</th>
<th>Primary UICC stage</th>
<th>Primary treatment</th>
<th>Site of recurrence</th>
<th>Time to recurrence (months)</th>
<th>Concomitant systemic therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>60</td>
<td>male</td>
<td>OC</td>
<td>IVA</td>
<td>def CRT (70.4 Gy)</td>
<td>T</td>
<td>34</td>
<td>cisplatin</td>
</tr>
<tr>
<td>#2</td>
<td>69</td>
<td>male</td>
<td>Larynx</td>
<td>IVA</td>
<td>adj CRT (63.9 Gy)</td>
<td>T</td>
<td>6</td>
<td>cetuximab</td>
</tr>
<tr>
<td>#3</td>
<td>55</td>
<td>male</td>
<td>OP</td>
<td>IVA</td>
<td>def CRT (70.4 Gy)</td>
<td>T + N</td>
<td>12</td>
<td>nivolumab</td>
</tr>
<tr>
<td>#4</td>
<td>60</td>
<td>male</td>
<td>OP</td>
<td>IVA</td>
<td>def CRT (70.4 Gy)</td>
<td>T</td>
<td>25</td>
<td>cisplatin</td>
</tr>
<tr>
<td>#5</td>
<td>60</td>
<td>male</td>
<td>HP</td>
<td>IVA</td>
<td>def CRT (70.4 Gy)</td>
<td>T + N</td>
<td>58</td>
<td>cisplatin</td>
</tr>
<tr>
<td>#6</td>
<td>67</td>
<td>female</td>
<td>OP</td>
<td>IVA</td>
<td>adj CRT (63.9 Gy)</td>
<td>T + N</td>
<td>38</td>
<td>cisplatin</td>
</tr>
<tr>
<td>#7</td>
<td>55</td>
<td>male</td>
<td>OC</td>
<td>IVA</td>
<td>def CRT (70.4 Gy)</td>
<td>T</td>
<td>9</td>
<td>cisplatin</td>
</tr>
<tr>
<td>#8</td>
<td>57</td>
<td>male</td>
<td>OC</td>
<td>IVB</td>
<td>adj CRT (63.9 Gy)</td>
<td>N</td>
<td>8</td>
<td>cisplatin</td>
</tr>
</tbody>
</table>
Table 2. FDG-PET, FMISO-PET and MRI parameters. Abbreviations: MTV = metabolic tumor volume, SUV\textsubscript{max} = maximum standardized uptake value, SUV\textsubscript{mean} = mean standardized uptake value, TMR\textsubscript{max} = maximum tumor-to-muscle ratio, HV\textsuperscript{1.6} = hypoxic volume with a threshold of 1.6 times the average background/muscle uptake; ADC = apparent diffusion coefficient.

<table>
<thead>
<tr>
<th>Patient Number</th>
<th>FDG MTV (ml)</th>
<th>FDG SUV\textsubscript{max}</th>
<th>FDG SUV\textsubscript{mean}</th>
<th>FMISO SUV\textsubscript{max}</th>
<th>FMISO SUV\textsubscript{mean}</th>
<th>FMISO TMR\textsubscript{max}</th>
<th>FMISO HV\textsuperscript{1.6} (ml)</th>
<th>Contrast enhancement relative to the reference</th>
<th>Average ADC value (10\textsuperscript{6} mm\textsuperscript{2}/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>#1</td>
<td>0.95</td>
<td>5.9</td>
<td>5.1</td>
<td>1.0</td>
<td>0.6</td>
<td>1.8</td>
<td>0.1*</td>
<td>more intense</td>
<td>1,357</td>
</tr>
<tr>
<td>#2</td>
<td>31.3</td>
<td>18.3</td>
<td>11.5</td>
<td>1.3</td>
<td>0.9</td>
<td>1.59</td>
<td>0</td>
<td>less intense</td>
<td>1,050</td>
</tr>
<tr>
<td>#3</td>
<td>51.7</td>
<td>20.1</td>
<td>12.6</td>
<td>0.7</td>
<td>0.4</td>
<td>1.12</td>
<td>0</td>
<td>less intense</td>
<td>1,000</td>
</tr>
<tr>
<td>#4</td>
<td>10.7</td>
<td>12.1</td>
<td>7.6</td>
<td>1.0</td>
<td>0.8</td>
<td>1.79</td>
<td>1.0</td>
<td>more intense (periphery)</td>
<td>1,400</td>
</tr>
<tr>
<td>#5</td>
<td>2.5</td>
<td>9.3</td>
<td>6.0</td>
<td>0.8</td>
<td>0.7</td>
<td>1.18</td>
<td>0</td>
<td>more intense (periphery)</td>
<td>1,060</td>
</tr>
<tr>
<td>#6</td>
<td>12.0</td>
<td>9.3</td>
<td>6.4</td>
<td>2.0</td>
<td>1.6</td>
<td>1.84</td>
<td>7.3</td>
<td>more intense</td>
<td>n.a. (CT only)</td>
</tr>
<tr>
<td>#7</td>
<td>11.6</td>
<td>9.3</td>
<td>6.2</td>
<td>0.9</td>
<td>0.6</td>
<td>1.79</td>
<td>0.1*</td>
<td>less intense</td>
<td>840</td>
</tr>
<tr>
<td>#8</td>
<td>7.2</td>
<td>5.0</td>
<td>3.0</td>
<td>0.6</td>
<td>0.4</td>
<td>1.4</td>
<td>0</td>
<td>less intense</td>
<td>1,065</td>
</tr>
</tbody>
</table>

\*Only a single voxel above the threshold

Figure 1. Patient examples. Examples of patients with local recurrence of a larynx cancer (left; patient #2), cervical lymph node metastasis (middle; patient #3) or oropharyngeal cancer relapse (right; patient #4), respectively. Fused FDG-PET/CT above, corresponding contrast-enhanced T1w MRI (StarVIBE) in the middle, and FMISO-PET below. In each patient, FDG uptake of the recurrent lesion is extensive and high, while specific FMISO uptake was absent (HV\textsuperscript{1.6} ≤ 1.0 ml).
absent. To the best of our knowledge, there is only one study that investigated various tumor locations and histologies with hypoxia PET. In the mentioned study, the authors describe one patient with recurrent adenocarcinoma of the uterus who showed a relatively high uptake of FMISO. It is not clear if this patient was previously treated with radiotherapy/CRT or presented recurrence after initial surgery21,22.

Very surprisingly, the incidence of hypoxia, determined by FMISO-PET, was extremely low in our study investigating recurrent HNSCC. The largest analysis of hypoxia PET images from five European centers established the hypoxia parameter $\text{TMR}_{\text{max}} > 2.0$ as a suitable value to distinguish high- and low-risk treatment-naive patients. The prevalence of hypoxia (defined as $\text{TMR}_{\text{max}} > 2.0$) was relatively high in primary tumors. PET hypoxia was found in 48% of all patients; among those who received FMISO-PET, 61% showed hypoxic tumors/lesions18. In the present trial of previously irradiated HNSCC, none of the eight included patients showed hypoxic tumors according to these cut-off values, despite the fact that patients with relatively large recurrent lesions were included (see Table 2). This finding may indicate that microenvironmental mechanisms of tumor radioresistance might be very different between treatment-naïve and previously irradiated tumors. This also seems to be the case with genetic alterations23,34. Dose painting for re-irradiation does not seem feasible in FMISO-PET due to the low tracer uptake, i.e. low rates of hypoxia in this patient collective [25,26,p.33].

In addition to late static FMISO-PET images, dynamic acquisition from 0 to 40 min post injection has been proposed. Combining dynamic and static PET images for a voxel-wise 2-compartment model of $[^{18}]$F-FMISO accumulation, Thorwarth et al. were able to identify patients with treatment-naïve HNSCC with either favorable or very poor local tumor control after radiotherapy. The derived dynamic parameter $M_{\text{FMISO}}$ was superior to $\text{TMR}_{\text{max}}$ in predicting local tumor control35. Dynamic FMISO-PET acquisition was not available in our patient collective. However, it is questionable if dynamic data would provide any added value in lesions that are negative on late FMISO images.

In addition to mostly absent hypoxia, ADC values were relatively high in all tumors with a median of $>1,000 \times 10^{-6} \text{ mm}^2/\text{s}$, which corresponds to only mildly restricted diffusion. Only in one tumor (patient #7), the average ADC was below $1,000 \times 10^{-6} \text{ mm}^2/\text{s}$. These MRI findings are consistent with the literature36,37,39. Hwang et al. reported average ADC values of 1,200 $\times 10^{-6} \text{ mm}^2/\text{s}$ in patients with recurrent HNSCC after initial treatment compared to an average of 1,650 $\times 10^{-6} \text{ mm}^2/\text{s}$ in lesions corresponding to post-therapeutic changes39. Previous reports on the association between tissue hypoxia in different tumor entities and properties in DWI or corresponding ADC maps are inconsistent. Hino-Shishikura et al. reported a negative correlation between ADC values and the SUV$_{\text{max}}$ and tumor-to-background ratios in brain tumors obtained with hypoxia-specific PET imaging37. Hompland et al. demonstrated a weak negative correlation between ADC values and hypoxic fraction assessed by pimonidazole tissue staining in malignant melanoma xenografts. Moreover, ADC values as high as $1,000 \times 10^{-6} \text{ mm}^2/\text{s}$ were only observed in tumors with hypoxic volumes <10% of the total tumor volume32. In contrast, a positive correlation was reported in murine melanoma tumors (but imaging was performed ex vivo31). Swartz et al. and Carmona-Bozo et al. found no correlation between hypoxia and ADC values in oropharyngeal and breast cancer lesions, respectively3,4,33.

Contrast enhancement (StarVIBE MRI sequence or contrast-enhanced CT) was atypically low in 4/8 lesions, and hypoxia was also absent in these tumors (Table 2). Among the 4/8 lesions with substantial contrast enhancement (at least in the tumor periphery), some showed small hypoxic proportions as determined by the FMISO HV$_{1,e}$. Gerstner et al. found that high lesional cerebral blood flow in glioblastoma quantified by dynamic susceptibility contrast MRI correlated positively with the hypoxic volume in FMISO-PET. The authors postulated that abnormal tumor vasculature contributes to hypoxia36. This may explain the lack of substantial and extensive contrast enhancement in the current mostly non-hypoxic tumors. However, the current sample size was too small to conclude if there is a negative correlation between contrast enhancement and tumor hypoxia. Dynamic contrast MRI sequences were not evaluated in this study, and contrast kinetics – as described by 36 – could not be assessed.

In summary, the current pilot study implies that relevant hypoxia, which is detectable by static FMISO-PET, may not be as prevalent among recurrent lesions of HPV negative HNSCC as expected. However, studies with substantially larger sample sizes would be required for a definite statement or more differentiated analyses (e.g., dependence of hypoxia on the type and localization of the recurrent lesion). This is also true for the investigation of a possible association of low tumor hypoxia with high ADC values and low contrast enhancement in these recurrent lesions. However, recruitment of HPV negative recurrent HNSCC into time consuming imaging trials remains challenging. Patient compliance is often low and comorbidities can hamper acquisition of sophisticated PET/ MRI protocols.

**Data availability**

All data underlying the results are available as part of the article (concerning absolute values of imaging parameters). Original imaging data cannot be made publicly available due to concerns regarding data protection since the imaging data contained several high-resolution methods with unique personal properties. German data protection is not only restricted by Ethics committees, but also by dedicated data protection agencies. One general concern of German data protection agencies, including Charité data protection commission, is that image information that is uploaded to public available repositories might be accessed by countries that do not comply with current data protection agreements. Therefore, pseudonymized data can be shared upon reasonable request by contacting the corresponding author. Access to the data will be granted after ethical approval and after ensuring that adequate data protection is adhered by the country of the applicant.
Extended data
Figshare: Supplementary figures with FDG and FMISO PET images of patients #4 and #6
https://doi.org/10.6084/m9.figshare.14170061.v3

This project contains the following underlying data:

- Supplementary Figure 1. (Patient #4 with FDG PET (first row) and fused FDG-PET CT (second row) and hypoxia FMISO PET (third row) with fused MRI (last row). The FDG volume is automatically segmented within the yellow sphere. Applying the 1.6 muscle threshold within this sphere leads to scattered hypoxic volumes without clear relation to the macroscopic tumor.)
- Supplementary Figure 2. (Patient #6 with FDG-PET (first row), fused CT image (second row), FMISO PET (third row) and FMISO-PET CT (last row). This time the 1.6 hypoxic threshold shows a hypoxic volume within the macroscopic tumor and only little extra-tumoral uptake in the surroundings.)

Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

References


Open Peer Review

Current Peer Review Status:  ✔   ✔

Version 2

Reviewer Report 17 March 2021

https://doi.org/10.5256/f1000research.55191.r81544

© 2021 Picchio M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Maria Picchio

1 Unit of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy
2 Vita-Salute San Raffaele University, Milan, Italy

In the revised form of the manuscript the limitations of the very limited and heterogeneous population are still present. However, an explanation has been provided for all the points underlined by the reviewers. I have no further comments to make.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Molecular Imaging in oncology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 01 March 2021

https://doi.org/10.5256/f1000research.30169.r79089

© 2021 Picchio M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Maria Picchio

1 Unit of Nuclear Medicine, IRCCS San Raffaele Scientific Institute, Milan, Italy
2 Vita-Salute San Raffaele University, Milan, Italy
The present manuscript deals with a very interesting issue reporting preliminary data on the use of a PET radiotracer, 18F-FMISO, to measure hypoxia in head and neck squamous cell carcinoma patients with relapse after previous irradiation. Eight patients have been included, 7/8 studied by FMISO PET/MRI and 1/8 by using PET/CT.

As for strengths, the paper is very well written and methodologically correct. In addition, although 18F-FMISO is a well-established prognostic factor in head and neck squamous cell carcinomas treated with definitive chemoradiation, data on prevalence and characteristics of PET measured hypoxia in patients with relapse after previous irradiation are still missing. This paper report imaging findings of pretherapeutic PET and MRI scans within a prospective trial.

As weakness, the number of patients included is very limited and the population is heterogeneous. In addition, two different scanners have been used (7 PET/MRI and 1 PET/CT). The rationale and the use of FDG in this preliminary evaluation has not been definitely defined and commented.

It should be also clarified why 1.6-fold muscle has been considered to define hypoxic volume. In literature other values have been also reported (i.e. 1.2; 1.4)

Is the work clearly and accurately presented and does it cite the current literature?  
Yes

Is the study design appropriate and is the work technically sound?  
Yes

Are sufficient details of methods and analysis provided to allow replication by others?  
Yes

If applicable, is the statistical analysis and its interpretation appropriate?  
Yes

Are all the source data underlying the results available to ensure full reproducibility?  
Yes

Are the conclusions drawn adequately supported by the results?  
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Molecular Imaging in oncology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
Sebastian Zschaecck, Charité-Universitätsmedizin Berlin, Berlin, Germany

We thank the reviewer for her helpful and positive comments

As weakness, the number of patients included is very limited and the population is heterogeneous. In addition, two different scanners have been used (7 PET/MRI and 1 PET/CT). The rationale and the use of FDG in this preliminary evaluation has not been definitely defined and commented.

We agree that the number of patients is limited and somehow heterogenous (especially regarding surgery). However, one has to bear in mind the low compliance of this group of HPV negative HNSCC and local relapse. Therefore it was already relatively difficult to recuit these patients into a trial with time consuming additional imaging - as a side note, only 1/3 of all screened patients could be recruited to this trial. Usually the same PET-MRI scanner was used, however due to severe claustrophobia one patient was scanned on the PET-CT. FDG is routinely used for re-irradiation in our department for staging and better target delineation. Additionally FDG PET should be used to define regions of FDG and hypoxia overlap within the macroscopic recurrent tumor. We added these information accordingly.

It should be also clarified why 1.6-fold muscle has been considered to define hypoxic volume. In literature other values have been also reported (i.e. 1.2; 1.4)

We fully agree that other thresholds have been reported. The 1.6 fold score is taken from the current meta-analysis. However, even this relatively high threshold led to scattered hypoxia volumes inside and outside the macroscopic tumor lesions. For better illustration we included images of the two patients with (small) HV1.6 volumes inside the macrospic tumor (#4 and #6) as supplementary information and hope that this visualizes that a true hypoxic volume can probably only defined in patient #6.

Competing Interests: No competing interests were disclosed.

Reviewer Report 02 December 2020

https://doi.org/10.5256/f1000research.30169.r75138

© 2020 Kelly J. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jacqueline Kelly
Department of Therapeutic Radiology, Yale School of Medicine, New Haven, CT, USA
In this manuscript, the authors explore the novel and important question of hypoxia levels in recurrent HNSCC that has previously been irradiated with high-dose RT. Because hypoxia has been shown to be prognostic in the definitive HNSCC RT setting, and as re-RT is toxic and may be effective in only very select patient populations, the knowledge gained from this study could be used to select appropriate candidates who may be more likely to have a durable response to re-RT. Surprisingly, the incidence of hypoxia was extremely low in the present study, albeit in a very limited number of patients in a heterogeneous patient population.

The paper is well-written, with clear methodology, presentation of the results, and an appropriate discussion. In viewing Table 1, it appears initial treatment was uniform, with def CRT patients receiving 70.4 Gy and adj CRT receiving 63.9. Since these doses are clearly not achieved using the commonly used 2Gy/fraction, it may be worth mentioning the fractionation schedule used with the initial treatment course. Altered fractionation schedules have at least theoretical advantages relative to OER effects and thus this should simply be noted.

I would also recommend in the conclusion reiterating that these findings apply to only the HPV(-) HNSCC population.

Overall, a soundly conducted study, unfortunately with conclusions limited by a very low number of patients.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Radiation therapy, radiation biology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
We thank the reviewer for her useful comments. We included a description of the initial treatment schedule (definitive and adjuvant CRT). Both regimes are applied according to clinical guidelines, using simultaneous integrated boost. However, the slight increase of single dose (2.13 or 2.2 Gray) is probably within the range that can be regarded normo-fractionated (1.8 to 2.0 or 2.2 Gray, according to definition), therefore we do not expect a major impact on OER.

We added the limitation that these findings apply only to HPV negative HNSCC in the abstract and in the results section.

**Competing Interests:** No competing interests were disclosed.